Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of 225Ac-ETN029 in advanced DLL3-expressing solid tumors
jRCT2031260233Phase 1Recruiting
- Sponsor
- Novartis
- Start
- Jul 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Small Molecules
01
Overview
Phase 1, open-label trial of [225Ac]Ac-ETN029 in small cell lung cancer (SCLC), large cell neuroendocrine carcinoma (LCNEC), neuroendocrine prostate cancer (NEPC) and 8 more (2 arms), sponsored by Novartis. Primary endpoints: Number of patients with dose-limiting toxicities of 225Ac-ETN029, Incidence and severity of adverse events and serious adverse events of 225Ac-ETN029 and 2 more. Started Jul 2026; status: recruiting.
02
Drugs
[225Ac]Ac-ETN029
03
Conditions
small cell lung cancer (SCLC)large cell neuroendocrine carcinoma (LCNEC)neuroendocrine prostate cancer (NEPC)gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC)cervical neuroendocrine carcinoma (NECC)
Beyond the preview
Go deeper on jRCT2031260233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260233.